All news

OBX short interest jumps 249.5% as shares sit near 52-week low

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Obsidian Therapeutics (NASDAQ:OBX) experienced a significant 249.5% surge in short interest in September, reaching 884,528 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average target price of $39.00. The company, which focuses on engineered cell and gene therapies, saw its shares trade at

Read original source

OBX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.